This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M07.2 | Special Copayment Reduction: V237 (severe intractable disease, 5 years) |
| B. Synonyms | Psoriasis-associated spondyloarthritis, psoriatic spondyloarthropathy, psoriatic axial spondyloarthropathy |
| C. Adult onset | Adult onset: very high — psoriatic spondylitis is the axial involvement form of psoriatic arthritis and mainly develops in adults (30s–50s). |
| 1. History | See main text |
| 2. Causes | See main text |
| 3. Genetics | See main text |
| 4. General epidemiology | See main text |
| 5. Pathophysiology | See main text |
| 6. Symptoms | See main text |
| 7. Signs | See main text |
| 8. Screening | See main text |
| 9. Diagnosis | See main text |
| 10. Treatment | See main text |
| 11. Prognosis | See main text |
| 12. Prevention | See main text |
| 13. References | See main text |
The history of psoriatic arthritis (PsA) began in 1818 when the French physician Jean-Louis Alibert first described joint involvement in patients with psoriasis. However, psoriatic arthritis was established as a distinct clinical entity separate from rheumatoid arthritis in 1964, when Bernard Blumberg and Hollander reported that rheumatoid factor was negative in the joint fluid of psoriasis patients. In 1973, Wright and Moll described five clinical subtypes of psoriatic arthritis (asymmetric small joint arthritis, distal interphalangeal joint arthritis, rheumatoid arthritis-like form, spondylitis form, and arthritis mutilans).
In 2006, the CASPAR (ClASsification criteria for Psoriatic ARthritis) classification criteria for psoriatic arthritis were published, greatly improving diagnostic accuracy. With the introduction of biologics (anti-TNF, anti-IL-17, anti-IL-23), treatment outcomes of PsA improved greatly, and since the 2010s JAK inhibitors (tofacitinib, upadacitinib) and a PDE4 inhibitor (apremilast) have been additionally approved.
Psoriatic spondylitis is the axial spinal involvement subtype of psoriatic arthritis; it resembles ankylosing spondylitis (AS), but has a lower HLA-B27 positivity rate (about 40–60% vs more than 90% in AS), asymmetric spinal changes, and a higher proportion of unilateral sacroiliitis. In the 1973 classification of psoriatic arthritis into five subtypes by Moll and Wright, the spondylitis type was described as an independent subtype. The efficacy of anti-IL-17 and anti-IL-23 agents in axial PsA has been demonstrated since the 2010s.
The cause of psoriatic arthritis is a combined action of genetic predisposition, environmental factors, and immunological abnormalities. HLA-B27 has a high positivity rate in the spondylitis form (about 50-60%), and HLA-B38, HLA-B39, HLA-Cw6, and others are also associated. In GWAS, IL-12B, IL-23R, TNFAIP3, TRAF3IP2, and others are associated with PsA susceptibility. Skin and joint trauma (the joint analogue of the Koebner phenomenon), streptococcal infection, smoking, and obesity are triggering factors. The IL-23/Th17 axis, TNF-α, and IL-17A/F are the main inflammatory cytokines.
HLA-B27 shows a strong association with the spinal phenotype. IL-17A and IL-23 contribute to inflammation of ligaments, joint capsules, and paraspinal tissue and to new bone formation (syndesmophytes). Mechanical stress and enthesopathy (inflammation at ligament attachment sites) are important factors in the development of spinal lesions.
The strongest genetic association in psoriatic arthritis is in the HLA region. HLA-Cw6 (PSORS1) is closely associated with psoriatic skin lesions, and HLA-B27 is associated with the spondyloarthritis phenotype (spondylitis, sacroiliitis). In GWAS, IL-12B (p40 subunit), IL-23R (R381Q variant), TRAF3IP2 (ACT1), TNFAIP3 (A20), RUNX3, TYK2, and others have been identified as psoriatic arthritis susceptibility genes. The IL-23R variant provides a biological basis explaining the high efficacy of anti-IL-23 biologics.
HLA-B27 is observed less frequently (40–60%) in psoriatic spondylitis than in ankylosing spondylitis. HLA-B27-negative psoriatic spondylitis may differ somewhat in clinical characteristics from HLA-B27-positive AS. Variants of ERAP1 (endoplasmic reticulum aminopeptidase 1) are associated with HLA-B27-positive spondyloarthritis.
Psoriatic arthritis occurs in about 20-30% of patients with psoriasis. The overall prevalence is about 0.1-0.25% of the general population and is estimated at about 0.1% in Korea. Arthritis develops on average 10-15 years after the diagnosis of psoriasis, but in some patients arthritis appears before psoriasis. The incidence in men and women is nearly equal. The median age at diagnosis is in the 30s to 50s.
Psoriatic spondylitis presents as purely axial involvement in about 5–10% of psoriatic arthritis, and including mixed forms (axial + peripheral), about 30–50% have axial involvement. Diagnostic delay is common, with an average delay of 5–7 years reported.
The pathophysiology of psoriatic arthritis centers on the IL-23/Th17 axis. Plasmacytoid dendritic cells (pDC) and dendritic cells in the skin produce IL-23, which activates Th17 cells and ILC3, and IL-17A, IL-17F, and IL-22 are secreted. In the joints, secretion of IL-17 and IL-22 by tissue-resident memory T cells (T_RM) promotes synovial inflammation. TNF-α, IL-6, and IL-1β also contribute to joint destruction. Bone erosion progresses through osteoclast activation caused by RANKL overexpression. On the other hand, new bone formation (periosteal new bone formation) is also a feature of PsA, and the dual 'destructive and constructive' presentation, in which joint ankylosis and bone proliferation appear simultaneously, is specific.
The characteristic symptom is inflammatory back pain: gradual onset, before age 40, severe morning stiffness lasting 1 hour or more, improvement with exercise and worsening with rest, buttock pain (alternating). Cervical and thoracic spine pain and limited range of motion may also occur. Peripheral arthritis, dactylitis, enthesitis (Achilles tendon, plantar fascia, etc.), eye involvement (uveitis), skin psoriasis, and nail psoriasis may accompany.
With progression, increased thoracic kyphosis, decreased lumbar hyperextension, and decreased chest expansion appear. Reduced Schober test. On radiographs, sacroiliitis (unilateral or bilateral) and asymmetric syndesmophytes (sometimes sparsely distributed). On MRI, bone marrow edema (acute inflammation) and fat deposition (chronic change) in the spine and sacroiliac joints. HLA-B27 positive (about 50–60%), elevated CRP/ESR.
In patients diagnosed with psoriatic arthritis who have inflammatory back pain, perform early imaging evaluation (X-ray, MRI). Classify axial involvement with reference to the ASAS/EULAR spondyloarthritis criteria. HLA-B27 testing is used as a diagnostic aid, but even if negative, additional evaluation by MRI is performed when clinical suspicion is high.
Psoriatic arthritis is confirmed by the CASPAR criteria. Evaluation of axial involvement: X-ray (pelvis–lumbar spine AP and lateral, sacroiliac joints), MRI (bone marrow edema confirmed on STIR sequence). Differentiation from AS: HLA-B27 positivity rate (AS >90% vs psoriatic spondylitis ~50%), symmetry of spinal changes, and accompanying psoriasis and nail psoriasis. Differentiation from reactive arthritis and enteropathic spondyloarthritis (with IBD) is also necessary.
NSAIDs are first-line treatment. With inadequate response to NSAIDs, switch to biologic agents. Anti-IL-17 (secukinumab, ixekizumab) and anti-TNF (adalimumab, etanercept, certolizumab, golimumab) are effective in axial psoriatic spondylitis for reducing bone edema and improving symptoms. Anti-IL-23 (guselkumab) is under study for efficacy in axial PsA but has limited efficacy in ankylosing spondylitis (pure AS). Physical therapy and exercise are important for maintaining spinal function. csDMARDs (MTX, leflunomide) are ineffective for axial involvement but are used to treat accompanying peripheral arthritis.
The prognosis of psoriatic spondylitis is relatively good with aggressive treatment, but delays in diagnosis and treatment accelerate structural spinal damage (syndesmophytes, spinal ankylosis). Biologic agents can slow structural progression. Management of accompanying uveitis, cardiovascular disease, and metabolic syndrome affects overall prognosis.
In psoriasis patients, early screening for psoriatic arthritis (including axial symptoms) and early referral to rheumatology are key. Use NSAIDs early to control symptoms and suppress structural damage. Smoking cessation and regular exercise (swimming, core strengthening) are important for maintaining spinal function. Tuberculosis screening before starting biologic agents, and maintenance of vaccinations (pneumococcal, influenza).